文献速递药物不良反应与药物警戒

欧洲患者组织在药物警戒中的作用

The Role of European Patient Organizations in Pharmacovigilance.
PubMed 文献 · Drug Saf · 2019-01-01

该研究于2018年3–4月通过网络问卷对欧洲患者组织进行描述性相关研究,共收集337份问卷(17.76%),来自31个国家。结果显示部分组织愿提升患者对特定药品不良反应的认知,但38.54%无药物警戒目标,主要障碍为预算低、资源缺乏和国家主管机构支持不足。

要点

  • 38.54%的受访患者组织没有药物警戒目标。
  • 主要障碍为预算低(45.45%)、资源缺乏(43.77%)和缺乏国家主管机构支持(33.33%)。
  • 34.68%的组织从未参与药物警戒活动。

核心结论

  • 将药物警戒利益相关方与患者组织联合可能营造更优的报告文化。
  • 患者组织可鼓励患者与医生或药师讨论不良反应,或协助其向药物警戒系统报告。

研究设计与样本

  • 描述性相关研究,于2018年3月和4月通过基于网络的问卷调查患者组织的意见和态度。
  • 邀请1898个患者组织参与,包括89个泛欧组织;收集337份问卷(17.76%),来自31个国家,其中297份完整(88.31%)。

主要发现

  • 43.19%(n=130)的组织表示希望提高患者对其药物相关特定不良反应的认知。
  • 38.54%(n=116)的组织声明没有任何药物警戒目标。
  • 40.40%(n=120)的组织告知患者报告不良反应,40.07%(n=119)告知药物相关新不良反应信息,30.98%(n=92)告知新药上市信息。
  • 34.68%(n=103)的组织表示从未参与过药物警戒。

关键数值与推荐

  • 支持药物警戒活动的障碍包括:促进成员间药物警戒的预算低(45.45%,n=135)。
  • 缺乏参与药物警戒活动的资源(43.77%,n=130)。
  • 缺乏国家主管机构的支持(33.33%,n=99)。

临床怎么用

  • 临床药学智能体可参考患者组织在鼓励患者报告不良反应和与医生药师沟通中的作用。
  • 关注患者组织在药物警戒中资源、预算和国家主管机构支持不足的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient organizations have a privileged position to be active agents for promoting pharmacovigilance and patient engagement, encouraging direct patient reporting and improving the awareness of pharmacovigilance. AIM: The objective of this study was to understand the role of European patient organizations as stakeholders to optimize patient involvement in pharmacovigilance. METHODS: A descriptive correlational study was conducted to investigate the opinions and attitudes of patient organizations regarding general patient involvement in pharmacovigilance, and their initiatives to support drug safety through a web-based questionnaire during the months of March and April 2018. RESULTS: A total of 1898 patient organizations were invited to participate in the survey, including 89 pan-European organizations. In total, 337 questionnaires (17.76%) were collected from 31 countries, including 297 complete answers (88.31%). A large number of organizations stated that they would like to increase the awareness of patients regarding specific adverse drug reactions (ADRs) related to their medicines (43.19%, n = 130); however, 38.54% (n = 116) declared they do not have any pharmacovigilance goals. Barriers to supporting pharmacovigilance activities include low budget to promote pharmacovigilance among members (45.45%, n = 135), lack of resources to participate in pharmacovigilance activities (43.77%, n = 130), or lack of support from the National Competent Authorities (33.33%, n = 99). Organizations inform patients to report ADRs (40.40%; n = 120), information regarding new ADRs related to their medicines (40.07%; n = 119), or when a new drug is marketed (30.98%; n = 92); however, more than one-third indicated that they never had any involvement in pharmacovigilance (34.68%; n = 103). CONCLUSION: Bringing pharmacovigilance stakeholders and patient organizations together could create a more optimal reporting culture. Patient organizations appear to have an important role in encouraging patients to talk with their doctors/pharmacists about ADRs experienced, or to help him/her report the ADRs to the pharmacovigilance systems. Lack of resources, budget, and support from NCAs are seen as the main barriers to being involved in pharmacovigilance awareness.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Matos C, Weits G, van Hunsel F, et al. The Role of European Patient Organizations in Pharmacovigilance. Drug Saf. 2019. PMID: 30357648. doi:10.1007/s40264-018-0748-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。